Soluble FcεRI is a potential biomarker for therapeutic response to omalizumab in patients with chronic spontaneous urticaria

被引：0
作者：
Moino-Romero, S. [1 ,2 ,3 ]
Kolkhir, P. [1 ,2 ,4 ]
Szepfalusi, Z. [3 ]
Hawro, T. [1 ,2 ]
Weller, K. [1 ,2 ]
Metz, M. [1 ,2 ]
Maurer, M. [1 ,2 ]
Altrichter, S. [1 ,2 ]
机构：
[1] Charite Univ Med Berlin, Dept Dermatol & Allergy, Allergie Ctr Charite, Dermatol Allergol, Berlin, Germany
[2] Humboldt Univ, Freie Univ Berlin, Berlin, Germany
[3] Med Univ Vienna, Dept Pediat & Adolescent Med, Vienna, Austria
[4] IM Sechenov First Moscow State Med Univ Sechenov, Div Immune Mediated Skin Dis, Moscow, Russia
来源：
EXPERIMENTAL DERMATOLOGY | 2021年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P070
引用
收藏
页码：E36 / E36
页数：1
相关论文
共 50 条
  • [1] Soluble FceRI is a potential biomarker for poor therapeutic response to omalizumab in patients with chronic spontaneous urticaria
    Moino-Romero, S.
    Kolkhir, P.
    Szepfalusi, Z.
    Maurer, M.
    Altrichter, S.
    EXPERIMENTAL DERMATOLOGY, 2023, 32 (04) : E47 - E47
  • [2] Response of FcεRI-bearing leucocytes to omalizumab in chronic spontaneous urticaria
    Aghdam, Mehran Alizadeh
    Knol, Edward F.
    van den Elzen, Mignon
    Jager, Constance den Hartog
    van Os-Medendorp, Harmieke
    Knulst, Andre C.
    Otten, Henny G.
    Rockmann, Heike
    CLINICAL AND EXPERIMENTAL ALLERGY, 2020, 50 (03) : 364 - 371
  • [3] Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy
    Deza, Gustavo
    Bertolin-Colilla, Marta
    Pujol, Ramon M.
    Curto-Barredo, Laia
    Soto, Dulce
    Garcia, Maribel
    Hernandez, Pilar
    Gimeno, Ramon
    Gimenez-Arnau, Ana M.
    ACTA DERMATO-VENEREOLOGICA, 2017, 97 (06) : 698 - 704
  • [4] Basophil FcεRI expression is linked to time to omalizumab response in chronic spontaneous urticaria
    Deza, Gustavo
    Bertolin-Colilla, Marta
    Sanchez, Silvia
    Soto, Dulce
    Pujol, Ramon M.
    Gimeno, Ramon
    Gimenez-Arnau, Ana M.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 141 (06) : 2313 - 2316
  • [5] Therapeutic Strategy According to Differences in Response to Omalizumab in Patients With Chronic Spontaneous Urticaria
    Arnau A M, Gimenez
    Santiago A, Valero
    Tomas J, Bartra
    Presa I, Jauregui
    Labrador-Horrillo, M.
    Miquel F J, Miquel
    de Frutos J, Ortiz
    Sastre, J.
    Salvador J F, Silvestre
    Puga M, Ferrer
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2019, 29 (05) : 338 - 348
  • [6] Omalizumab treatment response in patients with chronic spontaneous urticaria
    Knezevic, Sandra
    Dujmovic-Hasanbegovic, Katarina
    Peternel, Sandra
    BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 : 377 - 378
  • [7] The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria
    Chang, Tse Wen
    Chen, Christina
    Lin, Chien-Jen
    Metz, Martin
    Church, Martin K.
    Maurer, Marcus
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : 337 - +
  • [8] Serum transglutaminase 2 activity as a potential biomarker of disease severity and response to omalizumab in chronic spontaneous urticaria
    Bae, Youin
    Kang, Sung Hun
    Park, Ju Ok
    Park, Gyeong-Hun
    Choi, Jeong-Hee
    ALLERGOLOGY INTERNATIONAL, 2020, 69 (02) : 304 - 306
  • [9] IgE as a predictor to omalizumab response in patients with chronic spontaneous urticaria
    Ensina, Luis Felipe
    Brandao, Larissa
    Arruda, Luisa Karla
    Serpa, Faradiba Sarquis
    Campos, Regis Albuquerque
    Valle, Solange Rodrigues Oliveira
    Criado, Paulo Ricardo
    Saini, Sarbjit Singh
    Criado, Roberta Fachini Jardim
    FRONTIERS IN ALLERGY, 2025, 5
  • [10] Treatment response to omalizumab in patients with refractory chronic spontaneous urticaria
    Syrigos, Nikolaos
    Grapsa, Dimitra
    Zande, Maria
    Tziotou, Marianna
    Syrigou, Ekaterini
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2018, 57 (04) : 417 - 422
12345